May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al evaluated whether afatinib prolonged progression-free survival vs platinum-base...

The ASCO Post

May 14, 2025

Oral Option Now Available for PPGL

The FDA approved belzutifan as the first oral therapy for advanced pheochromocytoma and paraganglioma in patients aged 12 years and older.

Conexiant

May 13, 2025

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed mono...

The ASCO Post

May 12, 2025

Democratizing Liquid Biopsy-Based Precision Oncology Biomarkers in the United States

Four national thought leaders discuss the latest advancements and practical applications of liquid biopsy in cancer diagnostics and treatment

The Pathologist

May 09, 2025

Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at...

The ASCO Post

May 09, 2025

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Two pivotal phase III trials presented at the 2024 ASH Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia, offering potentiall...

The ASCO Post

May 09, 2025

Is Clonal Cytopenia of Undetermined Significance Distinct From Lower-Risk Myelodysplastic Syndrome?

High-risk patients with clonal cytopenia of undetermined significance have very similar characteristics and outcomes as patients with lower-risk myelodysplastic syndrome (MDS), which can be informativ...

The ASCO Post

May 09, 2025

Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research

The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago....

The ASCO Post